LOGIN  |  REGISTER
Terns Pharmaceuticals
Recursion

Ardent Health Appoints Dave Styblo to Lead Investor Relations

September 03, 2024 | Last Trade: US$ 16.61 0.00 0.00

BRENTWOOD, Tenn. / Sep 03, 2024 / Business Wire / Ardent Health (NYSE: ARDT) today announced the appointment of Dave Styblo as senior vice president of investor relations. In his new role, Styblo will oversee Ardent’s investor relations program and serve as the primary liaison with investors, analysts and financial partners.

Styblo brings more than 20 years of investment experience, including time as a sell-side analyst covering the healthcare industry. He previously served as a senior vice president at Jefferies for more than a decade as an equity research analyst with a focus on healthcare services and managed care stocks.

Most recently, Styblo served as an independent investor relations advisor to healthcare companies. He began his career as a sell-side research associate at JPMorgan Chase/Bear Stearns & Co. Styblo is a graduate of the University of Virginia.

“Dave’s deep experience and industry knowledge will be a great asset as we continue to build strong relationships and share the Ardent story across the investment community,” said Ardent Health Chief Financial Officer Alfred Lumsdaine. “We are excited to welcome him to Ardent as we begin this new chapter as a public company.”

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.

Recursion

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page